Evidence map›Paper›PMID 33753991›Full record

ArticleJournal of Cancer2021

Prognostic significance of

Cong Deng, Chaozeng Si, Xu Ye, Qiang Zhou, Tiansheng Zeng, Zeyong Huang, Wenhui Huang, Pei Zhu, Qingfu Zhong, Zhihua Wu and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Cong DengDepartment of Clinical laboratory, The Second Affiliated Hospital, Guangzhou Medical University, 510260 Guangzhou, China.
Chaozeng SiDepartment of Information Center, China-Japan Friendship Hospital, 100029 Beijing, China.
Xu YeDepartment of Hematology, The Second Affiliated Hospital, Guangzhou Medical University, 510260 Guangzhou, China.
Qiang ZhouDepartment of Clinical laboratory, The Second Affiliated Hospital, Guangzhou Medical University, 510260 Guangzhou, China.
Tiansheng ZengDepartment of Hematology, The Second Affiliated Hospital, Guangzhou Medical University, 510260 Guangzhou, China.
Zeyong HuangDepartment of Hematology, The Second Affiliated Hospital, Guangzhou Medical University, 510260 Guangzhou, China.
Wenhui HuangDepartment of Hematology, The Second Affiliated Hospital, Guangzhou Medical University, 510260 Guangzhou, China.
Pei ZhuDepartment of Hematology, The Second Affiliated Hospital, Guangzhou Medical University, 510260 Guangzhou, China.
Qingfu ZhongDepartment of Hematology, The Second Affiliated Hospital, Guangzhou Medical University, 510260 Guangzhou, China.
Zhihua WuDepartment of Hematology, The Second Affiliated Hospital, Guangzhou Medical University, 510260 Guangzhou, China.
Huoyan ZhuDepartment of Hematology, The Second Affiliated Hospital, Guangzhou Medical University, 510260 Guangzhou, China.
Qing LinDepartment of Hematology, The Second Affiliated Hospital, Guangzhou Medical University, 510260 Guangzhou, China.
Wenjuan ZhangDepartment of Hematology, The Second Affiliated Hospital, Guangzhou Medical University, 510260 Guangzhou, China.
Lin FuDepartment of Hematology, The Second Affiliated Hospital, Guangzhou Medical University, 510260 Guangzhou, China.
Yongjiang ZhengDepartment of Hematology, Institute of Hematology, The Third Affiliated Hospital of Sun Yat-Sen University, 510630 Guangzhou, China.
Tingting QianDepartment of Hematology, The Second Affiliated Hospital, Guangzhou Medical University, 510260 Guangzhou, China.
Guangzhou Medical University · CNSecond Affiliated Hospital of Guangzhou Medical University · CNState Key Laboratory of Respiratory Disease · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) is a hematologic tumor with monoclonal proliferation of malignant plasma cells in the bone marrow. Fascin (FSCN) is an actin-binding protein that plays a crucial role in cell migration and invasion, contributing to tumor metastasis. There are three members (

Indexed as

biomarkerFSCNmultiple myelomaprognosis.

Identifiers

PMID33753991
PMCPMC7974516
OpenAlexW3132713846

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.